Key takeaways
Skyrizi (risankizumab) and Enbrel (etanercept) are both injectable medications used to treat autoimmune conditions, but they have some key differences. Skyrizi is an interleukin antagonist that targets IL-23 to reduce inflammation, while Enbrel is a TNF inhibitor that blocks TNF proteins to achieve a similar effect. Skyrizi is typically administered every 2 to 3 months after initial doses, whereas Enbrel requires weekly injections. Skyrizi is used for plaque psoriasis, psoriatic arthritis, and Crohn's disease, while Enbrel is approved for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. Enbrel can be used in children as young as 2 years old for certain conditions, but Skyrizi is only approved for adults. Both medications can increase the risk of infections, but Enbrel also has warnings about potential cancer risks and nervous system effects.
